Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chemtura (CHMT) and Innospec (IOSP) upgraded to Overweight at KeyBanc by analyst Ivan Marcuse, who said the valuation for both companies is attractive and that 2016 estimates have potential upside. 2. Intercept (ICPT) upgraded to Overweight at KeyBanc by analyst Jim Birchenough after the FDA posted briefing documents for obeticholic acid in primary biliary cirrhosis ahead of Thursday's panel review. The analyst said the issues raised in the briefing document will not prevent a recommendation for approval. 3. Xylem (XYL) upgraded to Buy from Neutral at Sterne Agee CRT due to the belief that the company's organic revenue growth will accelerate above Street expectations, enabling its multiple to continue to rise. 4. Kimberly-Clark de Mexico (KCDMY) upgraded to Equal Weight at Barclays by analyst Benjamin Theurer, who cited lessening currency pressure and earnings growth potential. 5. TGS (TGS) upgraded to Outperform from Market Perform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.